Smoking associated with major urologic cancer surgical complications
the ONA take:
According to a study presented at the 2015 annual meeting of the American Urological Association in New Orleans, Louisiana, researchers have found that smokers and previous smokers are more likely to experience complications during and after major urologic cancer surgery and that quitting smoking for even just 1 year significantly improves surgical outcomes.
For the study, researchers identified 9,014 patients who underwent surgery for bladder, kidney, or prostate cancer from the American College of Surgeons National Surgical Quality Improvement Program database and identified.
Results showed current smokers had an increased risk for pulmonary and kidney complications and longer duration of hospitalization after prostate cancer surgery. In addition, patients with bladder cancer who currently smoked had an increased risk for requiring further surgery and former smokers had an increased risk for readmission.
Patients with prostate cancer who had not smoked for at least 1 year prior to surgery had a similar risk for surgical complications as non-smokers and had a significantly lower risk than current smokers.
The findings suggest that health care providers should motivate patients to quit smoking prior to undergoing major surgery in order to reduce the risk for complications.
Smokers and previous smokers are more likely to experience complications during and after major urologic cancer surgery.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|